ArticleCureus2025
Long-Term Joint Function and Quality of Life Following Emicizumab Prophylaxis in Severe Hemophilia A: A Single-Center Study From Goa, India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hemophilia A (HA) is an established inherited bleeding condition caused by the lack of factor VIII, which causes recurrent joint hemorrhages and related adverse outcomes. Emicizumab, a bispecific monoclonal antibody, provides sustained prophylaxis, minimizing bleeding episodes and enhancing treatment adherence. This study assesses its impact on joint health, functional independence, and quality of life (QoL) in Indian patients with severe HA. Methodology This retrospective study, conducted at Goa Medical College, Goa, India, involved 20 patients with severe HA receiving emicizumab prophylactic therapy over a period of one year from January 2023 to January 2024. Outcomes were judged using the Hemophilia Joint Health Score (HJHS), annualized bleed rate (ABR), functional independence score in hemophilia (FISH), and the European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire for a period of one year. Ethical approval was secured for the study, and patient confidentiality was upheld. Results This study comprised 20 male participants (median age: 30.15 years), of whom 90% had severe HA and 55% had inhibitors present. Most (90%) participants were on an on-demand treatment protocol. At baseline, 90% of participants had target joints (mean: 4.7±2.51), and the mean ABR was 24.6±9.02. Over 12 months, HJHS decreased from 36.00 to 6.05 (p<0.001), FISH improved from 14.00 to 25.95 (p<0.001), and ABR dropped by 99.8% (median: 0.00, p<0.001). The EQ-5D-5L score significantly improved (p<0.001), indicating better QoL. Treatment adherence was 100%, with no adverse events (AEs). Conclusions Emicizumab demonstrated significant benefits in severe HA, including improved joint health, enhanced functional independence, and a better QoL over the course of 12 months. With 100% adherence and no AEs reported, it proves to be a feasible and well-tolerated prophylactic option. These findings support its long-term role in disease management, warranting further research in diverse patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.